Treatment of heart failure in real-world clinical practice: Findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction

Clinical Cardiology

Volumn 38, Issue 4, 2015, Pages 200-207

  Böhm, Michael ^a   Tschöpe, Carsten ^b   Wirtz, Jost Henner ^c   Lokies, Jan ^d   Turgonyi, Eva ^e   Bramlage, Peter ^f   Lins, Katharina ^e   Strunz, Anke M ^g   Tebbe, Ulrich ^h  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Cardiology Group Practice   (Germany)

^d Eickhoff Lokies Cardiology Group Practice   (Germany)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f Institute for Pharmacology und Preventive Medicine   (Germany)

^g PFIZER INC   (United States)

^h Lippe Detmold Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; MINERALOCORTICOID ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEART FAILURE; HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PHYSICIAN; PRESCRIPTION; QUALITY OF LIFE; SEX DIFFERENCE; WORK EXPERIENCE; AGED; CLINICAL TRIAL; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; REGISTER; VERY ELDERLY;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; REGISTRIES; STROKE VOLUME; SURVEYS AND QUESTIONNAIRES;

EID: 84928432874     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22375     Document Type: Article

References (28)

1. Zhang Y, Kilgore ML, Arora T, et al. Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int J Cardiol. 2013; 166: 230-235.
2. McMurray JJ,. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011; 13: 929-936.
3. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.
4. Lindley CM, Tully MP, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing. 1992; 21: 294-300.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302.
6. Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361: 1329-1338.
7. Tang AS, Wells GA, Talajic M, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 363: 2385-2395.
8. Konstam MA, Neaton JD, Dickstein K, et al. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial [published correction appears in Lancet. 2009;374:1888]. Lancet. 2009; 374: 1840-1848.
9. Packer M, Bristow MR, Cohn JN, et al. U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334: 1349-1355.
10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2013;34:158]. Eur Heart J. 2012; 33: 1787-1847.
11. Tebbe U, Tschöpe C, Wirtz JH, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014; 103: 665-673.
12. Quiroz R, Doros G, Shaw P, et al. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol. 2014; 113: 691-696.
13. von Scheidt W, Zugck C, Pauschinger M, et al. Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the Evidence-based Treatment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol. 2014; 103: 1006-1014.
14. Weinbrenner S, Langer T, Scherer M, et al. The German National Disease Management Guideline "Chronic Heart Failure" [article in German]. Dtsch Med Wochenschr. 2012; 137: 219-227.
15. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [published corrections appear in Eur J Heart Fail. 2009;11:110 and Eur J Heart Fail. 2010;12:416]. Eur J Heart Fail. 2008; 10: 933-989.
16. Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010; 12: 617-622.
17. Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013; 167: 1677-1687.
18. Di Franco A, Sarullo FM, Salerno Y, et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs. 2014; 14: 101-110.
19. Pastor-Pérez FJ, Manzano-Fernández S, Goya-Esteban R, et al. Heart rate control in chronic heart failure: resting versus mean heart rate with prolonged ambulatory ECG recording. Int J Cardiol. 2013; 170: e45-e47.
20. Kato N, Kinugawa K, Teruhiko I, et al. Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation. Int J Cardiol. 2014; 173: 331-333.
21. Ceconi C, Freedman SB, Tardif JC, et al. BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011; 146: 408-414.
22. Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50: 768-777.
23. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010; 122: 585-596.
24. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009; 302: 1658-1665.
25. Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013; 15: 1173-1184.
26. Maggioni AP, Dahlström U, Filippatos G, et al. Heart Failure Association of the European Society of Cardiology. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013; 15: 808-817.
27. de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail. 2009; 11: 85-91.
28. Allen LA, Shetterly SM, Peterson PN, et al. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ Heart Fail. 2014; 7: 43-50.